Neurocrine Biosciences Posts Double-Digit Q4 Sales Growth, Advances Three Pipeline Programs
Neurocrine Biosciences reported strong year-over-year Q4 2025 sales growth driven by its core neurological franchise and highlighted expansion in international markets. Management confirmed 2026 revenue guidance and noted advancing three pipeline candidates toward mid-stage clinical trials.
1. Q4 Earnings Highlights
Neurocrine Biosciences reported double-digit year-over-year revenue growth in Q4 2025, attributing the increase to strong performance of its neurological therapies. Management emphasized expansion into new international territories as a key driver of quarterly sales momentum.
2. 2026 Guidance and Pipeline Progress
The company reconfirmed its full-year 2026 revenue guidance, citing stable demand across its marketed products. Executives detailed progress on three mid-stage pipeline candidates, signaling potential milestone payments and future revenue streams.